1000/1000
Hot
Most Recent
Cytokine adsorption can resolve different complications characteristic of transplantation medicine, such as cytokine storm activation and blood ABO and immune incompatibilities. Cytokine adsorption is also performed for the treatment of various life-threatening conditions, such as endotoxic septic shock, acute respiratory distress syndrome, and cardiogenic shock, all potentially leading to adverse clinical outcomes during transplantation. After surgery, dysmetabolism and stress response limit successful graft survival and can lead to primary or secondary graft dysfunction. In this clinical context, and given that a major problem in transplant medicine is that the demand for organs far exceeds the supply, a technological innovation such as a hemoadsorption system could greatly contribute to increasing the number of usable organ donors.
Organ Targeted |
Model and Treatment | Effects of CA Therapy | References |
---|---|---|---|
Lung | Porcine EVLP + CA, then LuTx. | ↓ cytokines, ↑ oxygenation, ↑ compliance, ↓ pharmacotherapy. | [3][4][5] |
Porcine EVLP + CA, then LuTx. | ↓ coagulation and complement pathways, ↓ humoral immune response pathways. | [7] | |
Porcine EVLP + CA. | ↓ pulmonary oedema, ↓ electrolytes imbalance. | [2] | |
Porcine EVLP + CA, then LuTx + CA. | ↓ cytokines, ↓ immune cells, ↓ PGD. | [9] | |
Porcine post LuTx and CA. | ↓ cytokines, ↑ CO2 removal. | [10] | |
Human LuTx and CA. | ↓ neutrophil and monocyte activation markers. | [11] | |
Human EVLP + CA, then LuTx. | ↓ cytokines, ↓ in-hospital mortality. | [12] | |
Human intraoperative LuTx and CA. | ↓ neutrophil extracellular traps, ↓ AR and PGD. | [13] | |
Heart | Human CPB + CA. | ↓ hemodynamic and metabolic and organ instability. | [15][16] |
Human CPB + CA. | ↓ plasma-free hemoglobin and complement C3a and C5a. | [17] | |
Human CPB + CA. | ↑ IL-10 anti-inflammatory long-lasting effects. | [18] | |
Human CPB for infective endocarditis + CA. | ↓ cytokines but without resolution of hemodynamic instability and in-hospital mortality. | [19] | |
Human CBP for acute endocarditis + CA. | ↓ in vasopressor use but not significant. | [20] | |
Human intraoperative HTx and CA. | ↓ CRRT frequency. | [21] | |
Human donor heart resuscitation for HTx and CA. | Donor heart implantation after 7 h cold ischemia. | [22] | |
Human HTx and CPB and CA. | Control of heparin-induced thrombocytopenia in HTx. | [23] | |
Human VA-ECMO for giant-cell myocarditis and CA. | ↓ hemodynamic and metabolic and organ instability. | [24] | |
Human VA-ECMO for cardiogenic shock and CA. | ↓ lactate, ↑ urine output, ↓ in-hospital mortality. | [25] | |
Porcine DCD heart ex vivo perfusion and CA. | ↓ cytokines, ↓ markers of endothelial injury. | [26] | |
Kidney | Porcine kidney ex vivo perfusion and CA, then KTx. | ↑ IL-6 and IL-8 at reperfusion, ↑ mean renal blood flow, ↓ prostaglandin E2 and prostacyclin and thromboxane. | [27] |
Human FSGS + CA. | ↓ soluble urokinase plasminogen activator receptor. | [28] | |
Human FSGS + lipoprotein apheresis. | ↑ complete or partial remission of proteinuria, ↑ response rates to steroid or immunosuppressive therapy. | [29] | |
Human kidney ex vivo perfusion and CA, then KTx. | ↑ oxidative phosphorylation (OXPHOS), ↓ inflammatory pathway genes. | [30] | |
Human FSGS + CA. | ↓ proteinuria. | [31] | |
Liver | Human ALF + CA. | ↓ TNFα and CRP and procalcitonin and α1-fetoprotein. | [32] |
Human ACLF + CA. | ↓ TNFα, ↑ IL-6. | [33] | |
Human LF + CA. | ↓ TNFα, ↓ IL-6, ↓ IL-1, ↓ IL-10. | [34] | |
Human LF + CA. | ↓ bilirubin, ↓ ammonia, ↓ LDH, ↓ platelets. | [35] | |
Human LF + CA. | ↓ bilirubin. | [36] | |
Human hyperbilirubinemia + CA. | ↓ bilirubin. | [37] | |
Human ALF + CA. | ↓ bilirubin. | [38] | |
Human septic shock after LiTx + CA. | ↓ procalcitonin, ↓ endoxins, ↓ IL-6, ↓ IL-10. | [39] | |
Human hyperbilirubinemia + CA. | ↓ bilirubin. | [40] | |
Human ACLF + CA. | ↓ bilirubin. | [41] | |
Human ACLF + CA. | ↓ bilirubin. | [42] | |
Human hyperbilirubinemia + CA. | No change in 30-day hospital mortality. | [43] | |
Human pediatric hyperbilirubinemia + CA. | ↓ bilirubin. | [44] | |
Porcine DCD liver ex vivo perfusion and CA. | ↓ cytokines. | [45] |